News & Events

Upcoming Events

Thu, 12/1/2022 - 1:00 PM ET
Hear from experts about new therapies, updates, and ways to live well… more
Fri, 12/2/2022 - 1:00 PM ET
Online Event Location:  Facebook.com/LUNGevity Take… more
Tue, 12/6/2022 - 12:00 PM ET
For patients/survivors - Join us every Tuesday for this general… more
Thu, 12/8/2022 - 8:00 PM ET
For caregivers, family & friends - You don’t need to take on… more
Tue, 12/13/2022 - 12:00 PM ET
For patients/survivors - Join us every Tuesday for this general… more

Keeping the Heartbeat Off-Target in Cancer Therapy

Keeping the Heartbeat Off-Target in Cancer Therapy

Scientists unlock potential for a small cell lung cancer blood test

Scientists unlock potential for a small cell lung cancer blood test

AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022

AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022

Tarlatamab Shows Encouraging Anti-tumor Activity Against SCLC in Phase 1 Trial

Tarlatamab Shows Encouraging Anti-tumor Activity Against SCLC in Phase 1 Trial

Talazoparib Plus Low-Dose Temozolomide Bests Historical Controls in R/R ES-SCLC

Talazoparib Plus Low-Dose Temozolomide Bests Historical Controls in R/R ES-SCLC

Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure

Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure

Phanes Therapeutics' PT217 receives Orphan Drug Designation for small cell lung cancer from the FDA

Phanes Therapeutics' PT217 receives Orphan Drug Designation for small cell lung cancer from the FDA

Switching to Lurbinectedin Monotherapy Maintains, Improves Tumor Response for Relapsed Small Cell Lung Cancer

Switching to Lurbinectedin Monotherapy Maintains, Improves Tumor Response for Relapsed Small Cell Lung Cancer

Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Lung Cancer and Mesothelioma

Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Lung Cancer and Mesothelioma